Lara Martín Rizo, Marta Sánchez Gómez-Serranillos, Marcelo Domínguez Cantero,Luis Carlos Fernández Lisón,Irene Iglesias Peinado María Pilar Gómez-Serranillos Cuadrado
Background: The aim is to describe the potential interactions between oral antineoplastic agents and concomitant medication. Previous studies proved that oral antineoplastic agents are associated with significant drug-drug interactions. Methods: The retrospective observational study to detect the potential interactions drug between oral antineoplastic agents and concomitant medication. All drug interactions detected between concomitant medication and oral antineoplastic agents were recorded. All potential interactions were classified by database as C (monitor therapy), D (consider therapy modification) or X (avoid combination) risk level. The analysis was carried out with three different databases. A descriptive analysis was conducted, including into account the demographic and clinical data, as well as the drug most commonly prescribed in the analyzed treatment. Results: A total de 315 drug-drug interactions were detected in 222 treatments. The average drug-drug interactions per patients relative to the total was 1,4. Most of the patients included had at least one potential interaction between oral antineoplastic agents and concomitant treatment. The interactions were resolved by monitoring or dose adjustment. Most part of interactions detected was of pharmacokinetic type (71.1%). For drug-drug interactions with antineoplastic agents, 180 interactions (57%) were classified as category C, 58 interactions (18.4%) as category D and 77 interactions (24.6%) as category X. Conclusion: The study proved that oral antineoplastic agents can increase the risk of drug-drug interaction. The sensitivity observed when detecting an interaction is different between the databases consulted. It thus highlights the importance of determining the clinical relevance of oral chemotherapy drug-drug interactions. For this, multidisciplinary team’s participation is essential.